Our Science

ShilpaBio has innovated unique platforms positioned to provide business value to customers worldwide

Global pain-point

Small Volume manufacturing
High operation costs of cell culture media

Next Steps – Programs in development

ContiGly™ platform for Development of pathway engineered cells that enable tunable glycosylation
ContiSec™ platform for Development of pathway engineered cells that enhance longevity and secretion from cells

ShilpaBio’s solution

High density continuous bioprocess platform for production of biopharmaceuticals from small footprint facility - ContiMAb™ , ContiFuse™ & ContiVir™
Development of low-cost cell culture media and media kit to enable continuous processing

Know More About ContiMAb™ & ContiFuse™ Know More About ContiVir™

ShilpaBio’s Scientific Mission 2021-2025

Continuous bioprocess platform ContiMAb & ContiFuse platforms to enable penetration of biologics from 5% to 30% of the patient population. Our scientists leverage the platforms for biosimilars portfolio development.

We welcome partners who share the mutual goal of making high quality biopharmaceuticals affordable to patients globally.
Please write to [email protected] with your queries.